HCW Biologics Inc.
NASDAQ · us_market
No AI insight generated yet for this ticker.
HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and diseases in the United States. Its lead products include HCW11-018b, a novel, tetra-valent T-Cell engager; HCW11-040, a multifunctional fusion molecule that is a combination of cytokines and pembrolizumab; and HCW9302, injectable and interleukin 2 (IL-2) fusion protein complex, which is in phase 1 for alopecia areata diseases. The company also develops HCW9201, a fusion protein designed as a reagent to use in the production of natural killer (NK) cell-based therapies; HCW9206, a fusion protein designed as a reagent to use in the production of CAR-therapies for the treatment of infectious diseases; and HCW11-006, an immune cell stimulator. It has a license agreement with Wugen Inc. to develop cell therapy-based treatments; and a license, research and co-development agreement with WY Biotech Co., Ltd. for its preclinical molecules. HCW Biologics Inc. was incorporated in 2018 and is headquartered in Miramar, Florida.
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-05-14 | -0.44 | 0.37 | +184.09% |
| 2026-03-31 | -0.84 | -1.02 | -21.43% |
| 2025-11-14 | 1.58 | -2.02 | -227.85% |
| 2025-08-18 | 1.80 | -6.79 | -477.22% |
| 2025-03-28 | 3.60 | -3.20 | -188.89% |
| 2024-11-14 | -5.20 | -4.00 | +23.08% |
| 2024-08-14 | -7.20 | -16.00 | -122.22% |
| 2024-04-01 | -6.00 | -12.00 | -100.00% |
| 2023-11-14 | -5.20 | -5.60 | -7.69% |
| 2023-08-11 | -6.20 | -4.80 | +22.58% |
| 2023-05-09 | -6.40 | -5.60 | +12.50% |
| 2023-03-28 | -5.80 | -6.00 | -3.45% |
| 2022-11-07 | -5.20 | -4.40 | +15.38% |
| 2022-08-12 | -5.00 | -4.00 | +20.00% |
| 2022-05-13 | -5.60 | -2.40 | +57.14% |
| 2022-03-29 | -4.80 | -2.40 | +50.00% |
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| HCWB | +338.05% | +200.00% | +103.91% | -74.39% |
| XLV | +2.97% | -4.64% | -3.44% | +12.69% |
| Alpha (stock − sector) | +335.08% | +204.64% | +107.36% | -87.07% |